HSH2D (hematopoietic SH2 domain containing) is an adapter protein that modulates immune and apoptotic responses. It functions in CD28-mediated T cell activation through signaling pathways that regulate interleukin-2 promoter activation 1. HSH2D is involved in protein-macromolecule adaptor activity and affects tyrosine kinase signaling downstream of CD28 1. At the molecular level, HSH2D exhibits regional epigenetic variation in lung macrophages, with differential DNA methylation associated with metabolic differences between upper and lower lung lobes 2. The gene is dysregulated in multiple disease contexts: it is downregulated in T-cell acute lymphoblastic leukemia compared to B-cell ALL, and HSH2D expression is necessary for methotrexate resistance in T-ALL cells 1. HSH2D is upregulated in doxorubicin-resistant colon cancer cells and serves as a poor prognostic marker, correlating with interferon signaling genes involved in chemoresistance 3. Additionally, HSH2D is upregulated in ulcerative colitis relative to Crohn's disease and functions as a T-cell activator in inflammatory bowel disease 4. Clinically, HSH2D represents a potential therapeutic target for overcoming drug resistance in cancer and managing inflammatory conditions through modulation of T cell activation and immune processes 1.